nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—multiple sclerosis	0.418	1	CrCtD
Pralatrexate—SLC19A1—Methotrexate—multiple sclerosis	0.111	0.426	CbGbCtD
Pralatrexate—FPGS—Methotrexate—multiple sclerosis	0.0799	0.308	CbGbCtD
Pralatrexate—Folic Acid—Methotrexate—multiple sclerosis	0.0552	0.2	CrCrCtD
Pralatrexate—Raltitrexed—Methotrexate—multiple sclerosis	0.0552	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—multiple sclerosis	0.0552	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—multiple sclerosis	0.0552	0.2	CrCrCtD
Pralatrexate—Pemetrexed—Methotrexate—multiple sclerosis	0.0552	0.2	CrCrCtD
Pralatrexate—DHFR—Methotrexate—multiple sclerosis	0.0406	0.156	CbGbCtD
Pralatrexate—TYMS—Methotrexate—multiple sclerosis	0.0283	0.109	CbGbCtD
Pralatrexate—Tumour lysis syndrome—Cladribine—multiple sclerosis	0.00157	0.0698	CcSEcCtD
Pralatrexate—DHFR—Nucleotide Metabolism—SRM—multiple sclerosis	0.00154	0.131	CbGpPWpGaD
Pralatrexate—FPGS—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00126	0.107	CbGpPWpGaD
Pralatrexate—Tumour lysis syndrome—Mitoxantrone—multiple sclerosis	0.00103	0.0459	CcSEcCtD
Pralatrexate—FPGS—retina—multiple sclerosis	0.000923	0.081	CbGeAlD
Pralatrexate—DHFR—Nucleotide Metabolism—RRM1—multiple sclerosis	0.00082	0.0698	CbGpPWpGaD
Pralatrexate—SLC19A1—nervous system—multiple sclerosis	0.000752	0.066	CbGeAlD
Pralatrexate—SLC19A1—central nervous system—multiple sclerosis	0.000724	0.0636	CbGeAlD
Pralatrexate—SLC19A1—cerebellum—multiple sclerosis	0.000708	0.0621	CbGeAlD
Pralatrexate—FPGS—medulla oblongata—multiple sclerosis	0.000667	0.0585	CbGeAlD
Pralatrexate—DHFR—retina—multiple sclerosis	0.0006	0.0526	CbGeAlD
Pralatrexate—FPGS—spinal cord—multiple sclerosis	0.000595	0.0522	CbGeAlD
Pralatrexate—SLC19A1—brain—multiple sclerosis	0.000575	0.0505	CbGeAlD
Pralatrexate—DHFR—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.000527	0.0448	CbGpPWpGaD
Pralatrexate—Liver function test abnormal—Fingolimod—multiple sclerosis	0.000515	0.0229	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Methotrexate—multiple sclerosis	0.000514	0.0228	CcSEcCtD
Pralatrexate—Neoplasm malignant—Cladribine—multiple sclerosis	0.00051	0.0227	CcSEcCtD
Pralatrexate—FPGS—nervous system—multiple sclerosis	0.000501	0.044	CbGeAlD
Pralatrexate—FPGS—central nervous system—multiple sclerosis	0.000483	0.0423	CbGeAlD
Pralatrexate—FPGS—cerebellum—multiple sclerosis	0.000472	0.0414	CbGeAlD
Pralatrexate—TYMS—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00046	0.0391	CbGpPWpGaD
Pralatrexate—DHFR—medulla oblongata—multiple sclerosis	0.000433	0.038	CbGeAlD
Pralatrexate—Neoplasm malignant—Azathioprine—multiple sclerosis	0.000415	0.0184	CcSEcCtD
Pralatrexate—TYMS—midbrain—multiple sclerosis	0.0004	0.0351	CbGeAlD
Pralatrexate—DHFR—midbrain—multiple sclerosis	0.000396	0.0347	CbGeAlD
Pralatrexate—DHFR—spinal cord—multiple sclerosis	0.000386	0.0339	CbGeAlD
Pralatrexate—FPGS—brain—multiple sclerosis	0.000383	0.0336	CbGeAlD
Pralatrexate—Sepsis—Cladribine—multiple sclerosis	0.000378	0.0168	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL4—multiple sclerosis	0.000348	0.0296	CbGpPWpGaD
Pralatrexate—TYMS—nervous system—multiple sclerosis	0.000329	0.0288	CbGeAlD
Pralatrexate—DHFR—nervous system—multiple sclerosis	0.000326	0.0286	CbGeAlD
Pralatrexate—Back pain—Fingolimod—multiple sclerosis	0.000325	0.0144	CcSEcCtD
Pralatrexate—TYMS—central nervous system—multiple sclerosis	0.000317	0.0278	CbGeAlD
Pralatrexate—Pain in extremity—Cladribine—multiple sclerosis	0.000316	0.0141	CcSEcCtD
Pralatrexate—DHFR—central nervous system—multiple sclerosis	0.000313	0.0275	CbGeAlD
Pralatrexate—TYMS—cerebellum—multiple sclerosis	0.000309	0.0271	CbGeAlD
Pralatrexate—DHFR—cerebellum—multiple sclerosis	0.000306	0.0269	CbGeAlD
Pralatrexate—Leukopenia—Fingolimod—multiple sclerosis	0.000301	0.0134	CcSEcCtD
Pralatrexate—Cough—Fingolimod—multiple sclerosis	0.000293	0.013	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Cladribine—multiple sclerosis	0.000285	0.0127	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—RRM1—multiple sclerosis	0.000279	0.0238	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—ICAM1—multiple sclerosis	0.000277	0.0235	CbGpPWpGaD
Pralatrexate—Pancytopenia—Cladribine—multiple sclerosis	0.000259	0.0115	CcSEcCtD
Pralatrexate—Neutropenia—Cladribine—multiple sclerosis	0.000255	0.0114	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Cladribine—multiple sclerosis	0.000254	0.0113	CcSEcCtD
Pralatrexate—TYMS—brain—multiple sclerosis	0.000251	0.022	CbGeAlD
Pralatrexate—DHFR—brain—multiple sclerosis	0.000249	0.0218	CbGeAlD
Pralatrexate—Sepsis—Mitoxantrone—multiple sclerosis	0.000248	0.011	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—CCL2—multiple sclerosis	0.000248	0.0211	CbGpPWpGaD
Pralatrexate—Dyspnoea—Fingolimod—multiple sclerosis	0.000244	0.0109	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—RRM1—multiple sclerosis	0.000244	0.0207	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000243	0.0207	CbGpPWpGaD
Pralatrexate—Fatigue—Fingolimod—multiple sclerosis	0.000236	0.0105	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Azathioprine—multiple sclerosis	0.000231	0.0103	CcSEcCtD
Pralatrexate—TYMS—Nucleotide metabolism—RRM1—multiple sclerosis	0.000231	0.0197	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—ALB—multiple sclerosis	0.000231	0.0196	CbGpPWpGaD
Pralatrexate—Epistaxis—Cladribine—multiple sclerosis	0.00023	0.0102	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000212	0.018	CbGpPWpGaD
Pralatrexate—Pancytopenia—Azathioprine—multiple sclerosis	0.000211	0.00938	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IFNG—multiple sclerosis	0.00021	0.0179	CbGpPWpGaD
Pralatrexate—Asthenia—Fingolimod—multiple sclerosis	0.000197	0.00874	CcSEcCtD
Pralatrexate—Pruritus—Fingolimod—multiple sclerosis	0.000194	0.00862	CcSEcCtD
Pralatrexate—Dehydration—Mitoxantrone—multiple sclerosis	0.000193	0.00859	CcSEcCtD
Pralatrexate—Hypokalaemia—Mitoxantrone—multiple sclerosis	0.000189	0.00841	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL1B—multiple sclerosis	0.000188	0.016	CbGpPWpGaD
Pralatrexate—Diarrhoea—Fingolimod—multiple sclerosis	0.000188	0.00834	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL2—multiple sclerosis	0.000187	0.0159	CbGpPWpGaD
Pralatrexate—Back pain—Cladribine—multiple sclerosis	0.000184	0.00819	CcSEcCtD
Pralatrexate—Anaemia—Cladribine—multiple sclerosis	0.000176	0.00782	CcSEcCtD
Pralatrexate—Pancytopenia—Mitoxantrone—multiple sclerosis	0.000171	0.00758	CcSEcCtD
Pralatrexate—Neutropenia—Mitoxantrone—multiple sclerosis	0.000168	0.00747	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	0.000167	0.00742	CcSEcCtD
Pralatrexate—Cough—Cladribine—multiple sclerosis	0.000166	0.00739	CcSEcCtD
Pralatrexate—Oedema—Cladribine—multiple sclerosis	0.000155	0.00691	CcSEcCtD
Pralatrexate—Thrombocytopenia—Cladribine—multiple sclerosis	0.000152	0.00676	CcSEcCtD
Pralatrexate—Tachycardia—Cladribine—multiple sclerosis	0.000152	0.00674	CcSEcCtD
Pralatrexate—Anorexia—Cladribine—multiple sclerosis	0.000148	0.00659	CcSEcCtD
Pralatrexate—Sepsis—Prednisone—multiple sclerosis	0.000148	0.00658	CcSEcCtD
Pralatrexate—Anaemia—Azathioprine—multiple sclerosis	0.000143	0.00636	CcSEcCtD
Pralatrexate—Leukopenia—Azathioprine—multiple sclerosis	0.000139	0.00616	CcSEcCtD
Pralatrexate—Dyspnoea—Cladribine—multiple sclerosis	0.000139	0.00616	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—TNF—multiple sclerosis	0.000136	0.0116	CbGpPWpGaD
Pralatrexate—Decreased appetite—Cladribine—multiple sclerosis	0.000135	0.00601	CcSEcCtD
Pralatrexate—Fatigue—Cladribine—multiple sclerosis	0.000134	0.00596	CcSEcCtD
Pralatrexate—Constipation—Cladribine—multiple sclerosis	0.000133	0.00591	CcSEcCtD
Pralatrexate—Hypokalaemia—Dexamethasone—multiple sclerosis	0.000129	0.00576	CcSEcCtD
Pralatrexate—Hypokalaemia—Betamethasone—multiple sclerosis	0.000129	0.00576	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000127	0.00565	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—SRM—multiple sclerosis	0.000127	0.0108	CbGpPWpGaD
Pralatrexate—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000126	0.0056	CcSEcCtD
Pralatrexate—Sepsis—Methotrexate—multiple sclerosis	0.000124	0.0055	CcSEcCtD
Pralatrexate—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000124	0.0055	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—IL4—multiple sclerosis	0.000124	0.0105	CbGpPWpGaD
Pralatrexate—Abdominal pain—Cladribine—multiple sclerosis	0.000123	0.00546	CcSEcCtD
Pralatrexate—Body temperature increased—Cladribine—multiple sclerosis	0.000123	0.00546	CcSEcCtD
Pralatrexate—Back pain—Mitoxantrone—multiple sclerosis	0.000121	0.00538	CcSEcCtD
Pralatrexate—Anaemia—Mitoxantrone—multiple sclerosis	0.000116	0.00514	CcSEcCtD
Pralatrexate—Epistaxis—Triamcinolone—multiple sclerosis	0.000114	0.00507	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000113	0.00961	CbGpPWpGaD
Pralatrexate—Hypokalaemia—Prednisone—multiple sclerosis	0.000113	0.00501	CcSEcCtD
Pralatrexate—Leukopenia—Mitoxantrone—multiple sclerosis	0.000112	0.00498	CcSEcCtD
Pralatrexate—Asthenia—Cladribine—multiple sclerosis	0.000111	0.00496	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL6—multiple sclerosis	0.00011	0.00935	CbGpPWpGaD
Pralatrexate—Pruritus—Cladribine—multiple sclerosis	0.00011	0.00489	CcSEcCtD
Pralatrexate—Cough—Mitoxantrone—multiple sclerosis	0.000109	0.00486	CcSEcCtD
Pralatrexate—FPGS—Metabolism—SRM—multiple sclerosis	0.000108	0.00918	CbGpPWpGaD
Pralatrexate—Diarrhoea—Cladribine—multiple sclerosis	0.000106	0.00473	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000103	0.00459	CcSEcCtD
Pralatrexate—Oedema—Mitoxantrone—multiple sclerosis	0.000102	0.00454	CcSEcCtD
Pralatrexate—Neutropenia—Prednisone—multiple sclerosis	0.0001	0.00445	CcSEcCtD
Pralatrexate—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.0001	0.00445	CcSEcCtD
Pralatrexate—Abdominal pain—Azathioprine—multiple sclerosis	9.99e-05	0.00444	CcSEcCtD
Pralatrexate—Body temperature increased—Azathioprine—multiple sclerosis	9.99e-05	0.00444	CcSEcCtD
Pralatrexate—Tachycardia—Mitoxantrone—multiple sclerosis	9.97e-05	0.00443	CcSEcCtD
Pralatrexate—Vomiting—Cladribine—multiple sclerosis	9.88e-05	0.00439	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—ICAM1—multiple sclerosis	9.82e-05	0.00836	CbGpPWpGaD
Pralatrexate—Rash—Cladribine—multiple sclerosis	9.8e-05	0.00436	CcSEcCtD
Pralatrexate—Dermatitis—Cladribine—multiple sclerosis	9.79e-05	0.00435	CcSEcCtD
Pralatrexate—SLC19A1—Disease—GPC5—multiple sclerosis	9.76e-05	0.00831	CbGpPWpGaD
Pralatrexate—Anorexia—Mitoxantrone—multiple sclerosis	9.73e-05	0.00433	CcSEcCtD
Pralatrexate—Liver function test abnormal—Methotrexate—multiple sclerosis	9.56e-05	0.00425	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	9.32e-05	0.00415	CcSEcCtD
Pralatrexate—Nausea—Cladribine—multiple sclerosis	9.23e-05	0.0041	CcSEcCtD
Pralatrexate—Back pain—Triamcinolone—multiple sclerosis	9.13e-05	0.00406	CcSEcCtD
Pralatrexate—Dyspnoea—Mitoxantrone—multiple sclerosis	9.1e-05	0.00405	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CYP27B1—multiple sclerosis	8.94e-05	0.00761	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CYP24A1—multiple sclerosis	8.94e-05	0.00761	CbGpPWpGaD
Pralatrexate—Decreased appetite—Mitoxantrone—multiple sclerosis	8.88e-05	0.00395	CcSEcCtD
Pralatrexate—Fatigue—Mitoxantrone—multiple sclerosis	8.8e-05	0.00392	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—CCL2—multiple sclerosis	8.79e-05	0.00748	CbGpPWpGaD
Pralatrexate—Constipation—Mitoxantrone—multiple sclerosis	8.73e-05	0.00388	CcSEcCtD
Pralatrexate—Diarrhoea—Azathioprine—multiple sclerosis	8.64e-05	0.00384	CcSEcCtD
Pralatrexate—Pancytopenia—Methotrexate—multiple sclerosis	8.5e-05	0.00378	CcSEcCtD
Pralatrexate—Oedema—Prednisolone—multiple sclerosis	8.38e-05	0.00373	CcSEcCtD
Pralatrexate—Neutropenia—Methotrexate—multiple sclerosis	8.37e-05	0.00372	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	8.35e-05	0.00371	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Methotrexate—multiple sclerosis	8.31e-05	0.0037	CcSEcCtD
Pralatrexate—FPGS—Disease—GPC5—multiple sclerosis	8.3e-05	0.00706	CbGpPWpGaD
Pralatrexate—Cough—Triamcinolone—multiple sclerosis	8.24e-05	0.00366	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—ALB—multiple sclerosis	8.19e-05	0.00697	CbGpPWpGaD
Pralatrexate—Tachycardia—Prednisolone—multiple sclerosis	8.18e-05	0.00364	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GPC5—multiple sclerosis	8.17e-05	0.00696	CbGpPWpGaD
Pralatrexate—Body temperature increased—Mitoxantrone—multiple sclerosis	8.07e-05	0.00359	CcSEcCtD
Pralatrexate—Abdominal pain—Mitoxantrone—multiple sclerosis	8.07e-05	0.00359	CcSEcCtD
Pralatrexate—Vomiting—Azathioprine—multiple sclerosis	8.03e-05	0.00357	CcSEcCtD
Pralatrexate—Rash—Azathioprine—multiple sclerosis	7.96e-05	0.00354	CcSEcCtD
Pralatrexate—Dermatitis—Azathioprine—multiple sclerosis	7.96e-05	0.00354	CcSEcCtD
Pralatrexate—Oedema—Triamcinolone—multiple sclerosis	7.7e-05	0.00343	CcSEcCtD
Pralatrexate—FPGS—Metabolism—CYP24A1—multiple sclerosis	7.6e-05	0.00647	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP27B1—multiple sclerosis	7.6e-05	0.00647	CbGpPWpGaD
Pralatrexate—Epistaxis—Methotrexate—multiple sclerosis	7.52e-05	0.00335	CcSEcCtD
Pralatrexate—Tachycardia—Triamcinolone—multiple sclerosis	7.52e-05	0.00334	CcSEcCtD
Pralatrexate—Nausea—Azathioprine—multiple sclerosis	7.5e-05	0.00334	CcSEcCtD
Pralatrexate—Tachycardia—Methylprednisolone—multiple sclerosis	7.5e-05	0.00334	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—IFNG—multiple sclerosis	7.47e-05	0.00636	CbGpPWpGaD
Pralatrexate—Asthenia—Mitoxantrone—multiple sclerosis	7.33e-05	0.00326	CcSEcCtD
Pralatrexate—TYMS—Azacitidine—Cladribine—multiple sclerosis	7.29e-05	0.0491	CbGdCrCtD
Pralatrexate—Oedema—Dexamethasone—multiple sclerosis	6.99e-05	0.00311	CcSEcCtD
Pralatrexate—Oedema—Betamethasone—multiple sclerosis	6.99e-05	0.00311	CcSEcCtD
Pralatrexate—Diarrhoea—Mitoxantrone—multiple sclerosis	6.99e-05	0.00311	CcSEcCtD
Pralatrexate—FPGS—Metabolism—GPC5—multiple sclerosis	6.95e-05	0.00591	CbGpPWpGaD
Pralatrexate—Anaemia—Prednisone—multiple sclerosis	6.89e-05	0.00307	CcSEcCtD
Pralatrexate—Dyspnoea—Triamcinolone—multiple sclerosis	6.87e-05	0.00305	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dexamethasone—multiple sclerosis	6.84e-05	0.00304	CcSEcCtD
Pralatrexate—Thrombocytopenia—Betamethasone—multiple sclerosis	6.84e-05	0.00304	CcSEcCtD
Pralatrexate—Tachycardia—Betamethasone—multiple sclerosis	6.82e-05	0.00303	CcSEcCtD
Pralatrexate—Tachycardia—Dexamethasone—multiple sclerosis	6.82e-05	0.00303	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—RRM1—multiple sclerosis	6.77e-05	0.00576	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—IL1B—multiple sclerosis	6.67e-05	0.00567	CbGpPWpGaD
Pralatrexate—Anorexia—Betamethasone—multiple sclerosis	6.66e-05	0.00296	CcSEcCtD
Pralatrexate—Anorexia—Dexamethasone—multiple sclerosis	6.66e-05	0.00296	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—IL2—multiple sclerosis	6.64e-05	0.00565	CbGpPWpGaD
Pralatrexate—Fatigue—Triamcinolone—multiple sclerosis	6.64e-05	0.00295	CcSEcCtD
Pralatrexate—Fatigue—Methylprednisolone—multiple sclerosis	6.63e-05	0.00295	CcSEcCtD
Pralatrexate—Vomiting—Mitoxantrone—multiple sclerosis	6.49e-05	0.00289	CcSEcCtD
Pralatrexate—Rash—Mitoxantrone—multiple sclerosis	6.44e-05	0.00286	CcSEcCtD
Pralatrexate—Dermatitis—Mitoxantrone—multiple sclerosis	6.43e-05	0.00286	CcSEcCtD
Pralatrexate—SLC19A1—Disease—RPL5—multiple sclerosis	6.35e-05	0.0054	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	6.29e-05	0.0028	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	6.18e-05	0.00526	CbGpPWpGaD
Pralatrexate—Body temperature increased—Triamcinolone—multiple sclerosis	6.09e-05	0.00271	CcSEcCtD
Pralatrexate—Oedema—Prednisone—multiple sclerosis	6.09e-05	0.00271	CcSEcCtD
Pralatrexate—SLC19A1—Disease—SLC11A1—multiple sclerosis	6.08e-05	0.00517	CbGpPWpGaD
Pralatrexate—Abdominal pain—Methylprednisolone—multiple sclerosis	6.08e-05	0.0027	CcSEcCtD
Pralatrexate—Decreased appetite—Betamethasone—multiple sclerosis	6.08e-05	0.0027	CcSEcCtD
Pralatrexate—Decreased appetite—Dexamethasone—multiple sclerosis	6.08e-05	0.0027	CcSEcCtD
Pralatrexate—Nausea—Mitoxantrone—multiple sclerosis	6.07e-05	0.0027	CcSEcCtD
Pralatrexate—Back pain—Methotrexate—multiple sclerosis	6.03e-05	0.00268	CcSEcCtD
Pralatrexate—Fatigue—Betamethasone—multiple sclerosis	6.03e-05	0.00268	CcSEcCtD
Pralatrexate—Fatigue—Dexamethasone—multiple sclerosis	6.03e-05	0.00268	CcSEcCtD
Pralatrexate—Tachycardia—Prednisone—multiple sclerosis	5.94e-05	0.00264	CcSEcCtD
Pralatrexate—Anorexia—Prednisone—multiple sclerosis	5.8e-05	0.00258	CcSEcCtD
Pralatrexate—Anaemia—Methotrexate—multiple sclerosis	5.76e-05	0.00256	CcSEcCtD
Pralatrexate—FPGS—Metabolism—RRM1—multiple sclerosis	5.76e-05	0.0049	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Dexamethasone—multiple sclerosis	5.72e-05	0.00254	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Betamethasone—multiple sclerosis	5.72e-05	0.00254	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—multiple sclerosis	5.58e-05	0.00248	CcSEcCtD
Pralatrexate—Asthenia—Triamcinolone—multiple sclerosis	5.53e-05	0.00246	CcSEcCtD
Pralatrexate—Abdominal pain—Dexamethasone—multiple sclerosis	5.53e-05	0.00246	CcSEcCtD
Pralatrexate—Abdominal pain—Betamethasone—multiple sclerosis	5.53e-05	0.00246	CcSEcCtD
Pralatrexate—Body temperature increased—Dexamethasone—multiple sclerosis	5.53e-05	0.00246	CcSEcCtD
Pralatrexate—Body temperature increased—Betamethasone—multiple sclerosis	5.53e-05	0.00246	CcSEcCtD
Pralatrexate—Asthenia—Methylprednisolone—multiple sclerosis	5.52e-05	0.00245	CcSEcCtD
Pralatrexate—Pruritus—Triamcinolone—multiple sclerosis	5.45e-05	0.00242	CcSEcCtD
Pralatrexate—Cough—Methotrexate—multiple sclerosis	5.44e-05	0.00242	CcSEcCtD
Pralatrexate—Pruritus—Methylprednisolone—multiple sclerosis	5.44e-05	0.00242	CcSEcCtD
Pralatrexate—FPGS—Disease—RPL5—multiple sclerosis	5.4e-05	0.00459	CbGpPWpGaD
Pralatrexate—Decreased appetite—Prednisone—multiple sclerosis	5.29e-05	0.00235	CcSEcCtD
Pralatrexate—Rash—Prednisolone—multiple sclerosis	5.28e-05	0.00235	CcSEcCtD
Pralatrexate—Dermatitis—Prednisolone—multiple sclerosis	5.28e-05	0.00235	CcSEcCtD
Pralatrexate—Diarrhoea—Methylprednisolone—multiple sclerosis	5.26e-05	0.00234	CcSEcCtD
Pralatrexate—Fatigue—Prednisone—multiple sclerosis	5.25e-05	0.00233	CcSEcCtD
Pralatrexate—Constipation—Prednisone—multiple sclerosis	5.21e-05	0.00232	CcSEcCtD
Pralatrexate—FPGS—Disease—SLC11A1—multiple sclerosis	5.17e-05	0.0044	CbGpPWpGaD
Pralatrexate—Asthenia—Betamethasone—multiple sclerosis	5.02e-05	0.00223	CcSEcCtD
Pralatrexate—Asthenia—Dexamethasone—multiple sclerosis	5.02e-05	0.00223	CcSEcCtD
Pralatrexate—Thrombocytopenia—Methotrexate—multiple sclerosis	4.98e-05	0.00222	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Prednisone—multiple sclerosis	4.98e-05	0.00221	CcSEcCtD
Pralatrexate—Nausea—Prednisolone—multiple sclerosis	4.98e-05	0.00221	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.97e-05	0.00423	CbGpPWpGaD
Pralatrexate—Pruritus—Dexamethasone—multiple sclerosis	4.95e-05	0.0022	CcSEcCtD
Pralatrexate—Pruritus—Betamethasone—multiple sclerosis	4.95e-05	0.0022	CcSEcCtD
Pralatrexate—Vomiting—Triamcinolone—multiple sclerosis	4.9e-05	0.00218	CcSEcCtD
Pralatrexate—Vomiting—Methylprednisolone—multiple sclerosis	4.89e-05	0.00217	CcSEcCtD
Pralatrexate—Rash—Triamcinolone—multiple sclerosis	4.86e-05	0.00216	CcSEcCtD
Pralatrexate—SLC19A1—Disease—CD28—multiple sclerosis	4.85e-05	0.00413	CbGpPWpGaD
Pralatrexate—Dermatitis—Triamcinolone—multiple sclerosis	4.85e-05	0.00216	CcSEcCtD
Pralatrexate—Anorexia—Methotrexate—multiple sclerosis	4.85e-05	0.00216	CcSEcCtD
Pralatrexate—Rash—Methylprednisolone—multiple sclerosis	4.85e-05	0.00216	CcSEcCtD
Pralatrexate—Dermatitis—Methylprednisolone—multiple sclerosis	4.84e-05	0.00215	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—TNF—multiple sclerosis	4.84e-05	0.00412	CbGpPWpGaD
Pralatrexate—Body temperature increased—Prednisone—multiple sclerosis	4.81e-05	0.00214	CcSEcCtD
Pralatrexate—Abdominal pain—Prednisone—multiple sclerosis	4.81e-05	0.00214	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—MYC—multiple sclerosis	4.79e-05	0.00408	CbGpPWpGaD
Pralatrexate—Diarrhoea—Dexamethasone—multiple sclerosis	4.78e-05	0.00213	CcSEcCtD
Pralatrexate—Diarrhoea—Betamethasone—multiple sclerosis	4.78e-05	0.00213	CcSEcCtD
Pralatrexate—TYMS—Clobetasol propionate—Methylprednisolone—multiple sclerosis	4.68e-05	0.0315	CbGdCrCtD
Pralatrexate—TYMS—Flunisolide—Methylprednisolone—multiple sclerosis	4.62e-05	0.0311	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Dexamethasone—multiple sclerosis	4.61e-05	0.031	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Betamethasone—multiple sclerosis	4.61e-05	0.031	CbGdCrCtD
Pralatrexate—Nausea—Triamcinolone—multiple sclerosis	4.58e-05	0.00204	CcSEcCtD
Pralatrexate—TYMS—Triamcinolone—Methylprednisolone—multiple sclerosis	4.57e-05	0.0308	CbGdCrCtD
Pralatrexate—Nausea—Methylprednisolone—multiple sclerosis	4.57e-05	0.00203	CcSEcCtD
Pralatrexate—TYMS—Flunisolide—Betamethasone—multiple sclerosis	4.55e-05	0.0306	CbGdCrCtD
Pralatrexate—TYMS—Flunisolide—Dexamethasone—multiple sclerosis	4.55e-05	0.0306	CbGdCrCtD
Pralatrexate—Dyspnoea—Methotrexate—multiple sclerosis	4.54e-05	0.00202	CcSEcCtD
Pralatrexate—DHFR—Metabolism—SRM—multiple sclerosis	4.51e-05	0.00383	CbGpPWpGaD
Pralatrexate—TYMS—Clobetasol propionate—Triamcinolone—multiple sclerosis	4.5e-05	0.0303	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Betamethasone—multiple sclerosis	4.5e-05	0.0303	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Dexamethasone—multiple sclerosis	4.5e-05	0.0303	CbGdCrCtD
Pralatrexate—TYMS—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	4.46e-05	0.03	CbGdCrCtD
Pralatrexate—Vomiting—Betamethasone—multiple sclerosis	4.44e-05	0.00198	CcSEcCtD
Pralatrexate—Vomiting—Dexamethasone—multiple sclerosis	4.44e-05	0.00198	CcSEcCtD
Pralatrexate—TYMS—Flunisolide—Triamcinolone—multiple sclerosis	4.44e-05	0.0299	CbGdCrCtD
Pralatrexate—Decreased appetite—Methotrexate—multiple sclerosis	4.42e-05	0.00197	CcSEcCtD
Pralatrexate—Rash—Betamethasone—multiple sclerosis	4.41e-05	0.00196	CcSEcCtD
Pralatrexate—Rash—Dexamethasone—multiple sclerosis	4.41e-05	0.00196	CcSEcCtD
Pralatrexate—Dermatitis—Betamethasone—multiple sclerosis	4.4e-05	0.00196	CcSEcCtD
Pralatrexate—Dermatitis—Dexamethasone—multiple sclerosis	4.4e-05	0.00196	CcSEcCtD
Pralatrexate—TYMS—Fluticasone Propionate—Betamethasone—multiple sclerosis	4.39e-05	0.0295	CbGdCrCtD
Pralatrexate—TYMS—Fluticasone Propionate—Dexamethasone—multiple sclerosis	4.39e-05	0.0295	CbGdCrCtD
Pralatrexate—Fatigue—Methotrexate—multiple sclerosis	4.39e-05	0.00195	CcSEcCtD
Pralatrexate—Asthenia—Prednisone—multiple sclerosis	4.37e-05	0.00194	CcSEcCtD
Pralatrexate—Pruritus—Prednisone—multiple sclerosis	4.31e-05	0.00192	CcSEcCtD
Pralatrexate—TYMS—Fluticasone Propionate—Triamcinolone—multiple sclerosis	4.29e-05	0.0289	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Prednisone—multiple sclerosis	4.27e-05	0.0288	CbGdCrCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.25e-05	0.00362	CbGpPWpGaD
Pralatrexate—TYMS—Flunisolide—Prednisone—multiple sclerosis	4.22e-05	0.0284	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Methylprednisolone—multiple sclerosis	4.21e-05	0.0284	CbGdCrCtD
Pralatrexate—TYMS—E2F transcription factor network—MYC—multiple sclerosis	4.18e-05	0.00356	CbGpPWpGaD
Pralatrexate—TYMS—Triamcinolone—Prednisone—multiple sclerosis	4.17e-05	0.0281	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Prednisolone—multiple sclerosis	4.17e-05	0.0281	CbGdCrCtD
Pralatrexate—Diarrhoea—Prednisone—multiple sclerosis	4.17e-05	0.00185	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	4.16e-05	0.00354	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.16e-05	0.00185	CcSEcCtD
Pralatrexate—Nausea—Betamethasone—multiple sclerosis	4.15e-05	0.00185	CcSEcCtD
Pralatrexate—Nausea—Dexamethasone—multiple sclerosis	4.15e-05	0.00185	CcSEcCtD
Pralatrexate—TYMS—Diflorasone—Betamethasone—multiple sclerosis	4.15e-05	0.0279	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Dexamethasone—multiple sclerosis	4.15e-05	0.0279	CbGdCrCtD
Pralatrexate—FPGS—Disease—CD28—multiple sclerosis	4.13e-05	0.00351	CbGpPWpGaD
Pralatrexate—TYMS—Flunisolide—Prednisolone—multiple sclerosis	4.12e-05	0.0277	CbGdCrCtD
Pralatrexate—TYMS—Circadian rythm related genes—FAS—multiple sclerosis	4.08e-05	0.00347	CbGpPWpGaD
Pralatrexate—TYMS—Triamcinolone—Prednisolone—multiple sclerosis	4.07e-05	0.0274	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Triamcinolone—multiple sclerosis	4.05e-05	0.0273	CbGdCrCtD
Pralatrexate—Abdominal pain—Methotrexate—multiple sclerosis	4.02e-05	0.00179	CcSEcCtD
Pralatrexate—Body temperature increased—Methotrexate—multiple sclerosis	4.02e-05	0.00179	CcSEcCtD
Pralatrexate—TYMS—Metabolism—SRM—multiple sclerosis	3.93e-05	0.00335	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—IL6—multiple sclerosis	3.9e-05	0.00332	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—BCHE—multiple sclerosis	3.89e-05	0.00331	CbGpPWpGaD
Pralatrexate—Vomiting—Prednisone—multiple sclerosis	3.87e-05	0.00172	CcSEcCtD
Pralatrexate—TYMS—Diflorasone—Prednisone—multiple sclerosis	3.85e-05	0.0259	CbGdCrCtD
Pralatrexate—Rash—Prednisone—multiple sclerosis	3.84e-05	0.00171	CcSEcCtD
Pralatrexate—Dermatitis—Prednisone—multiple sclerosis	3.83e-05	0.00171	CcSEcCtD
Pralatrexate—TYMS—Diflorasone—Prednisolone—multiple sclerosis	3.75e-05	0.0253	CbGdCrCtD
Pralatrexate—TYMS—Budesonide—Methylprednisolone—multiple sclerosis	3.69e-05	0.0249	CbGdCrCtD
Pralatrexate—Asthenia—Methotrexate—multiple sclerosis	3.65e-05	0.00162	CcSEcCtD
Pralatrexate—TYMS—Budesonide—Dexamethasone—multiple sclerosis	3.64e-05	0.0245	CbGdCrCtD
Pralatrexate—TYMS—Budesonide—Betamethasone—multiple sclerosis	3.64e-05	0.0245	CbGdCrCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	3.63e-05	0.00309	CbGpPWpGaD
Pralatrexate—Nausea—Prednisone—multiple sclerosis	3.62e-05	0.00161	CcSEcCtD
Pralatrexate—Pruritus—Methotrexate—multiple sclerosis	3.6e-05	0.0016	CcSEcCtD
Pralatrexate—TYMS—Budesonide—Triamcinolone—multiple sclerosis	3.55e-05	0.0239	CbGdCrCtD
Pralatrexate—Diarrhoea—Methotrexate—multiple sclerosis	3.48e-05	0.00155	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—MYC—multiple sclerosis	3.48e-05	0.00296	CbGpPWpGaD
Pralatrexate—DHFR—Disease—GPC5—multiple sclerosis	3.47e-05	0.00295	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CD86—multiple sclerosis	3.46e-05	0.00295	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Prednisone—multiple sclerosis	3.37e-05	0.0227	CbGdCrCtD
Pralatrexate—FPGS—Metabolism—BCHE—multiple sclerosis	3.31e-05	0.00281	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Prednisolone—multiple sclerosis	3.29e-05	0.0222	CbGdCrCtD
Pralatrexate—Vomiting—Methotrexate—multiple sclerosis	3.23e-05	0.00144	CcSEcCtD
Pralatrexate—TYMS—Danazol—Prednisone—multiple sclerosis	3.23e-05	0.0218	CbGdCrCtD
Pralatrexate—Rash—Methotrexate—multiple sclerosis	3.21e-05	0.00143	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—multiple sclerosis	3.2e-05	0.00143	CcSEcCtD
Pralatrexate—DHFR—Metabolism—CYP27B1—multiple sclerosis	3.17e-05	0.0027	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP24A1—multiple sclerosis	3.17e-05	0.0027	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CCR5—multiple sclerosis	3.07e-05	0.00261	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—MYC—multiple sclerosis	3.03e-05	0.00258	CbGpPWpGaD
Pralatrexate—Nausea—Methotrexate—multiple sclerosis	3.02e-05	0.00134	CcSEcCtD
Pralatrexate—SLC19A1—Disease—HLA-A—multiple sclerosis	2.99e-05	0.00255	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CD86—multiple sclerosis	2.94e-05	0.00251	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—multiple sclerosis	2.93e-05	0.00249	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GPC5—multiple sclerosis	2.9e-05	0.00247	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—APOE—multiple sclerosis	2.79e-05	0.00238	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP24A1—multiple sclerosis	2.77e-05	0.00236	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP27B1—multiple sclerosis	2.77e-05	0.00236	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CCR5—multiple sclerosis	2.61e-05	0.00222	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—multiple sclerosis	2.56e-05	0.00218	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HLA-A—multiple sclerosis	2.55e-05	0.00217	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GPC5—multiple sclerosis	2.53e-05	0.00216	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CD80—multiple sclerosis	2.53e-05	0.00215	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—RRM1—multiple sclerosis	2.41e-05	0.00205	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APOE—multiple sclerosis	2.38e-05	0.00202	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—APOE—multiple sclerosis	2.34e-05	0.00199	CbGpPWpGaD
Pralatrexate—DHFR—Disease—RPL5—multiple sclerosis	2.25e-05	0.00192	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC11A1—multiple sclerosis	2.16e-05	0.00184	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CD80—multiple sclerosis	2.15e-05	0.00183	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TYK2—multiple sclerosis	2.13e-05	0.00182	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—RRM1—multiple sclerosis	2.1e-05	0.00179	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—POMC—multiple sclerosis	2.01e-05	0.00171	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—APOE—multiple sclerosis	1.99e-05	0.00169	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.94e-05	0.00165	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.93e-05	0.00164	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CD4—multiple sclerosis	1.93e-05	0.00164	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.89e-05	0.00161	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ALB—multiple sclerosis	1.83e-05	0.00156	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TYK2—multiple sclerosis	1.81e-05	0.00154	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.8e-05	0.00154	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CD28—multiple sclerosis	1.72e-05	0.00147	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—POMC—multiple sclerosis	1.71e-05	0.00145	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CD4—multiple sclerosis	1.64e-05	0.0014	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ALB—multiple sclerosis	1.56e-05	0.00133	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—STAT3—multiple sclerosis	1.49e-05	0.00127	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—IL6—multiple sclerosis	1.4e-05	0.00119	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—multiple sclerosis	1.39e-05	0.00118	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TGFB1—multiple sclerosis	1.38e-05	0.00118	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—BCHE—multiple sclerosis	1.38e-05	0.00118	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MAPK1—multiple sclerosis	1.36e-05	0.00116	CbGpPWpGaD
Pralatrexate—FPGS—Disease—STAT3—multiple sclerosis	1.27e-05	0.00108	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CD86—multiple sclerosis	1.23e-05	0.00105	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—BCHE—multiple sclerosis	1.21e-05	0.00103	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—multiple sclerosis	1.18e-05	0.001	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TGFB1—multiple sclerosis	1.18e-05	0.001	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MAPK1—multiple sclerosis	1.15e-05	0.000982	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CCR5—multiple sclerosis	1.09e-05	0.000928	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—multiple sclerosis	1.07e-05	0.000914	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HLA-A—multiple sclerosis	1.06e-05	0.000905	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	1.05e-05	0.000895	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—IL6—multiple sclerosis	1.04e-05	0.000888	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APOE—multiple sclerosis	9.93e-06	0.000845	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—multiple sclerosis	9.61e-06	0.000818	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MAPK1—multiple sclerosis	9.4e-06	0.0008	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—multiple sclerosis	9.38e-06	0.000798	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	9.17e-06	0.000781	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CD80—multiple sclerosis	8.97e-06	0.000764	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IL6—multiple sclerosis	8.87e-06	0.000755	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—multiple sclerosis	8.38e-06	0.000713	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—APOE—multiple sclerosis	8.31e-06	0.000707	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MAPK1—multiple sclerosis	8.2e-06	0.000698	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TYK2—multiple sclerosis	7.58e-06	0.000645	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—APOE—multiple sclerosis	7.25e-06	0.000617	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—POMC—multiple sclerosis	7.14e-06	0.000608	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CD4—multiple sclerosis	6.85e-06	0.000583	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ALB—multiple sclerosis	6.51e-06	0.000554	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—POMC—multiple sclerosis	6.23e-06	0.00053	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ALB—multiple sclerosis	5.68e-06	0.000483	CbGpPWpGaD
Pralatrexate—DHFR—Disease—STAT3—multiple sclerosis	5.3e-06	0.000451	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—multiple sclerosis	4.93e-06	0.000419	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFB1—multiple sclerosis	4.92e-06	0.000418	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MAPK1—multiple sclerosis	4.82e-06	0.00041	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IL6—multiple sclerosis	3.71e-06	0.000315	CbGpPWpGaD
